Use of Nirsevimab and Palivizumab to Prevent Hospitalizations from Severe Respiratory Syncytial Virus (RSV) in High Risk Infants
The Office of MaineCare Services (OMS) is currently accepting Prior Authorization (PA) requests for coverage of palivizumab due to the increasing trend of positive RSV tests. The clinical benefit of palivizumab therapy is best realized by timing the administration to coincide with the peak of RSV activity.